Umuntu 1 yahitanwe na Covid-19 mu Rwanda,abandi 167 barayandura
Minisiteri y’Ubuzima iratangaza ko uyu munsi tariki ya 07 Mutarama 2021,Umuntu1 yahitanywe na COVID-19 abamaze kwicwa n’iki cyorezo bageze kuri 113 mu gihe abanduye bo bashya ari 167 bituma bagera ku 9,225.
Nta muntu wakize iki cyorezo mu masaha 24 ashize.
Uwitabye Imana n’umugore w’imyaka 46 wo mu Mujyi wa Kigali.
Itangazo rya Minisante ryerekana ko abarwayi 103 bakuwe I Kigali: 117, Musanze: 18, Nyamasheke: 9, Huye: 8, Kamonyi: 6, Rubavu: 6, Muhanga: 2, Gisagara: 1.
![](http://umuryango.rw/IMG/png/erj60rtxcamqdrn.png)
Kubera ko nta muntu n’umwe wakize,umubare w’abamaze gukira bose bagasezerwa mu bitaro bakomeje kuba 6,940 nyuma yo gupimwa bagasangwa nta bwandu bagifite mu gihe 2,172 barwaye bakiri kwitabwaho.
Abaturarwanda basabwa gukomeza kwitwararika no kubahiriza amabwiriza ya Leta hitabwa cyane cyane ku gukaraba intoki kenshi n’amazi n’isabune, kwirinda imihuro itari ngombwa no kwambara udupfukamunwa n’amazuru mu gihe umuntu avuye mu rugo cyangwa ahuye n’abantu benshi.
Ikigo Gishinzwe iby’Imiti cy’i Burayi cyamaze kwemeza urukingo rwa Moderna rwakorewe muri Leta Zunze Ubumwe z’Amerika, kivuga ko rwujuje ubuziranenge ndetse rufite ubushobozi bwo guhangana na Covid-19.
Urwo rukingo ruje kunganira urwa Pfizer BioNTech mu guterwa abaturage bo mu bihugu 27 bigize Umuryango w’Ubumwe bw’Uburayi (EU).
Uru rukingo rwemejwe na komite ishinzwe iby’imiti muri iki kigo, ruje mu gihe ibihugu by’i Burayi biri mu bihe bitoroshye, aho iki cyorezo cyongeye kikazahaza uyu mugabane ndetse ibihugu bimwe na bimwe bikaba byarasubiye muri Guma mu rugo.
Moderna kandi ije kunganira urukingo rwa Pfizer BioNTech, nyuma y’uko i Burayi bari batangiye kuzamura ibibazo by’uko izi nkingo zabaye nke muri gahunda yari yatangijwe na EU yo gukwirakwiza inkingo mu bihugu byose biyigize bituwe n’abaturage babarirwa muri miliyoni 450
Umuyobozi Mukuru w’Ikigo Gishinzwe iby’Imiti cy’i Burayi (EMA), Emer Cooke, yavuze ko urukingo rushya rugiye kubabera indi ntwaro yo guhashya icyorezo.
Comments are closed.